<DOC>
	<DOC>NCT02878863</DOC>
	<brief_summary>An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.</brief_summary>
	<brief_title>Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Autoimmune</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Peoniflorin</mesh_term>
	<criteria>Patients aged 2070 years; Diagnosed with AIH or primary biliary cirrhosisautoimmune hepatitis overlap syndrome based on liver biopsy results and without indication of immunosuppressive therapy; High levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)(13 X ULN); High levels of IgG(11.5 X ULN); Liver biopsy showed mild lymphocytic piecemeal necrosis (interface hepatitis); Agreed to participate in the trial, and assigned informed consent. The presence of hepatitis A, B, C, D, or E virus infection; Patients with presence of liver cirrhosis or portal hypertension; Patients with presence of fulminant liver failure; Primary sclerosing cholangitis, nonalcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy; Pregnant and breeding women; Severe disorders of other vital organs, such as severe heart failure, cancer; Parenteral administration of blood or blood products within 6 months before screening; Recent treatment with drugs having known liver toxicity; Taken part in other clinic trials within 6 months before screening.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>